Results 101 to 110 of about 18,145 (196)

Loss of ≥15 letters from baseline: (A) Ranibizumab versus laser, (B) Ranibizumab combined with laser versus laser, and (C) Ranibizumab combined with laser versus ranibizumab.

, 2014
RBZ  =  ranibizumab, RBZ + Laser  =  ranibizumab combined with laser; M-H  =  Mantel-Haenszel statistics; CI  =  confidence interval.
Yuhua Tong (513824), Wensheng Li (309393), Fangzheng Jiang (513822), Sihong Mao (513823), Guohai Chen (65113), Radouil Tzekov (309387)   +5 more
core   +1 more source

One-year results of intravitreal ranibizumab combined with reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy

, 2014
Madoka Sakurai, Takayuki Baba, Masayasu Kitahashi, Hirotaka Yokouchi, Mariko Kubota-Taniai, Guzel Bikbova, Toshiyuki Oshitari, Shuichi YamamotoDepartment of Ophthalmology and Visual Science, Chiba University Graduate School of Medicine, Chiba ...
Yokouchi H, Oshitari T, Baba T, Sakurai M, Yamamoto S, Kitahashi M, Bikbova G, Kubota-Taniai M   +7 more
core  

Mean change in best corrected visual acuity from baseline: (A) Ranibizumab versus laser, (B) Ranibizumab combined with laser versus laser, and (C) Ranibizumab combined with laser versus ranibizumab.

, 2014
RBZ  =  ranibizumab, RBZ + Laser  =  ranibizumab combined with laser; SD  =  standard deviation; IV  =  inverse variance; CI  =  confidence interval.
Yuhua Tong (513824), Wensheng Li (309393), Fangzheng Jiang (513822), Sihong Mao (513823), Guohai Chen (65113), Radouil Tzekov (309387)   +5 more
core   +1 more source

Effect of intravitreal ranibizumab on serous retinal detachment in branch retinal vein occlusion

, 2018
Emine Dogan,1 Ozkan Sever,2 Burcin Köklü Çakir,1 Erkan Celik1 1Department of Ophthalmology, Sakarya University Medical Education and Research Hospital, Sakarya, Turkey; 2Department of Ophthalmology, Namik Kemal University School of ...
Dogan E, Köklü Çakir B, Sever O, Celik E   +3 more
core  

Gain of ≥15 letters from baseline: (A) Ranibizumab versus laser, (B) Ranibizumab combined with laser versus laser, and (C) Ranibizumab combined with laser versus ranibizumab.

, 2014
RBZ  =  ranibizumab, RBZ + Laser  =  ranibizumab combined with laser; M-H  =  Mantel-Haenszel statistics; CI  =  confidence interval.
Yuhua Tong (513824), Wensheng Li (309393), Fangzheng Jiang (513822), Sihong Mao (513823), Guohai Chen (65113), Radouil Tzekov (309387)   +5 more
core   +1 more source

Single and multiple injections of subconjunctival ranibizumab for early, recurrent pterygium

, 2013
Volkan Hurmeric,1 Pravin Vaddavalli,1 Anat Galor,1,2 Victor L Perez,1 Janika San Roman,1 Sonia H Yoo11Bascom Palmer Eye Institute, University of Miami, Miller School of Medicine, Miami, FL, USA; 2Miami Veterans Affairs Medical Center, Miami, FL ...
Galor A, Yoo SH, Vaddavalli P, Perez VL, Hurmeric V, San Roman J   +5 more
core  

Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema

, 2017
Sameh Mosaad Fouda, Ahmed M Bahgat Department of Ophthalmology, Faculty of Medicine, Zagazig University, Zagazig, Egypt Purpose: The purpose of this study was to compare the efficacy of intravitreal aflibercept and ranibizumab in the treatment of ...
Bahgat AM, Fouda SM
core  

Critical appraisal of ranibizumab in the treatment of diabetic macular edema

, 2013
Michael W StewartDepartment of Ophthalmology, Mayo School of Medicine, Jacksonville, FL, USAAbstract: Diabetic retinopathy is the leading cause of blindness among individuals of working age in industrialized nations, with most of the vision loss ...
Stewart MW
core  

Ranibizumab in the treatment of patients with visual impairment due to diabetic macular edema

, 2011
Francesco Bandello1, Umberto De Benedetto1, Karl Anders Knutsson1, Maurizio Battaglia Parodi1, Maria Lucia Cascavilla1, Pierluigi Iacono21Department of Ophthalmology, University Vita-salute, Scientific Institute San Raffaele, Milan, Italy; 2Fondazione G ...
Knutsson KA, Iacono P, De Benedetto U, Cascavilla ML, Bandello F, Battaglia Parodi M   +5 more
core  

Ranibizumab versus verteporfin for neovascular age-related macular degeneration

, 2006
BACKGROUND: We compared ranibizumab--a recombinant, humanized, monoclonal antibody Fab that neutralizes all active forms of vascular endothelial growth factor A--with photodynamic therapy with verteporfin in the treatment of predominantly classic ...
ANCHOR, Study Group, Brown, DM, Kaiser, PK, Soubrane, G, Michels, M, Schneider, S, Heier, JS, Kim, RY, Sy, JP   +8 more
core   +1 more source